Imatinib mesylate-induced acute hepatotoxicity.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners(2023)
Abstract
Regular liver function test monitoring is recommended during imatinib treatment. In fact of acute hepatic toxicity, treatment with imatinib should be stopped in the case of cytolysis more than five times the upper limit of normal.
MoreTranslated text
Key words
Acute hepatotoxicity, Chronic myeloid leukemia, Imatinib mesylate
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined